InVivo Therapeutics Holdings Corporation
NVIVQ
Other OTC0.37
USD
+0.04
- -
ISIN
US46186M6057
CUSIP
46186M605
Return %
Stock
S&P500
1Y
-70.63
18.02
3Y
-97.57
64.11
5Y
-99.92
70.77
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Richard M. Toselli
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Kendall Square Cambridge MA United States of America 02139
- IPO Date
- Nov 15, 2010
- Website
- invivotherapeutics.com
- Similar Companies
- Business
- InVivo Therapeutics Holdings Corporation is a clinical-stage biotechnology company specializing in biomaterials and treatments for spinal cord injuries. The company develops and commercializes its primary product, the Neuro-Spinal Scaffold, an investigational bioresorbable polymer implant designed to be implanted at the site of acute spinal cord injury to support and promote neural tissue healing and minimize damage. Its product pipeline also includes bioengineered neural trails targeting spinal trauma. InVivo's technology utilizes biocompatible polymers such as poly lactic-co-glycolic acid and poly-L-lysine to provide structural support and enhance the body's natural repair mechanisms. The company primarily operates in the United States and is headquartered in Cambridge, Massachusetts. Founded in 2005, InVivo focuses on redefining patient outcomes in spinal cord injury treatment. Recent major developments include the completion of enrollment for its INSPIRE 2.0 clinical study, a 20-patient randomized trial aimed at generating enhanced clinical evidence for the Neuro-Spinal Scaffold. Topline data from this study was expected in early 2023. The company also closed a registered direct offering and private placement raising approximately $9 million to support working capital and potential commercialization efforts for its Neuro-Spinal Scaffold device. In addition, InVivo executed a 1-for-25 reverse stock split in April 2022 to comply with Nasdaq minimum bid price requirements. In early 2024, InVivo filed for Chapter 11 voluntary reorganization to restructure its finances while continuing development activities. These strategic financial maneuvers reflect InVivo’s efforts to advance commercialization and sustain operations amid ongoing clinical development. InVivo serves the biotechnology and medtech segments focusing on acute spinal cord injury patients and healthcare providers involved in trauma care. The company continues to engage in investor and scientific communications to support its clinical and regulatory pathways. Its growth strategy includes advancing clinical evidence, securing funding, and preparing for market entry of its Neuro-Spinal Scaffold technology. This summary provides an up-to-date view of InVivo Therapeutics Holdings Corporation’s core products, key clinical programs, recent financial activities, and corporate restructuring status as of late 2025.